Posttransplant lymphoproliferative disorders in lung transplant

Published

Journal Article (Review)

As the number of lung transplant recipients grows, so does the potential prevalence of PTLD. The recent introduction of the anti-CD20 monoclonal antibody, rituximab, into clinical practice has already improved our ability to successfully treat PTLD after lung transplant. Ongoing studies of the molecular pathogenesis of B-cell transformation by EBV will likely lead to additional novel immunologically based therapies effective in the prevention or treatment of PTLD. © 2004 Lippincott Williams & Wilkins.

Full Text

Duke Authors

Cited Authors

  • Snyder, LD; Palmer, SM

Published Date

  • January 1, 2004

Published In

Volume / Issue

  • 9 / 3

Start / End Page

  • 325 - 331

Electronic International Standard Serial Number (EISSN)

  • 1531-7013

International Standard Serial Number (ISSN)

  • 1087-2418

Digital Object Identifier (DOI)

  • 10.1097/01.mot.0000135415.90704.92

Citation Source

  • Scopus